Limits...
Clinical significance of migration and invasion inhibitor protein expression in non-small-cell lung cancer.

Wang X, Liu H, Wang X, An Y - Oncol Lett (2014)

Bottom Line: The results revealed that MIIP mRNA and protein expression were downregulated in cancer tissues, as compared with the matched normal tissues.MIIP expression levels were significantly associated with pathology and tumor stage, with reduced MIIP mRNA expression levels detected in advanced tumor stage samples.Furthermore, patients with MIIP-positive protein expression had an improved prognosis as compared with those patients with MIIP-negative protein expression, with five-year survival rates of 41.7 and 22.4%, respectively (Kaplan-Meier, log-rank, P=0.028).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China.

ABSTRACT
Migration and invasion inhibitor protein (MIIP) was initially identified in a yeast two-hybrid screen. Recently, MIIP has emerged as a key protein in regulating cell migration and invasion. However, the MIIP expression profile in non-small-cell lung cancer (NSCLC) has not been analyzed. In the present study, MIIP mRNA expression levels were evaluated using the SYBR Green quantitative real-time polymerase chain reaction method in 37 NSCLC specimens and matched normal tissue samples. MIIP protein expression in a further 94 NSCLC specimens was examined with immunohistochemistry. Patient survival data were collected retrospectively, and the association between MIIP protein expression and the five-year overall survival rate was evaluated. The results revealed that MIIP mRNA and protein expression were downregulated in cancer tissues, as compared with the matched normal tissues. MIIP expression levels were significantly associated with pathology and tumor stage, with reduced MIIP mRNA expression levels detected in advanced tumor stage samples. Furthermore, patients with MIIP-positive protein expression had an improved prognosis as compared with those patients with MIIP-negative protein expression, with five-year survival rates of 41.7 and 22.4%, respectively (Kaplan-Meier, log-rank, P=0.028). A significant association between MIIP protein expression and improved prognosis was also demonstrated using univariate and multivariate analyses (P=0.033 and P=0.040, respectively). These results suggest that MIIP may have a potential role in the pathogenesis of NSCLC and also confirm that MIIP is a putative tumor-suppressor gene. Therefore, MIIP may be identified as a functional genetic marker of NSCLC development and prognosis, and may be an attractive therapeutic target for the treatment of lung cancer.

No MeSH data available.


Related in: MedlinePlus

Examples of migration and invasion inhibitor protein immunostaining in non-small cell lung carcinoma samples. (A) Adenocarcinoma; and (B) squamous cell carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214401&req=5

f3-ol-08-06-2417: Examples of migration and invasion inhibitor protein immunostaining in non-small cell lung carcinoma samples. (A) Adenocarcinoma; and (B) squamous cell carcinoma.

Mentions: Immunohistochemical staining of MIIP in the cancer tissue sections was conducted. Immunoreactivity for the MIIP antibody was predominantly identified in the cytoplasm of cancer cells with marginal immunoreactivity in the nucleus (Fig. 3). Among the 94 tissue samples, MIIP protein expression was positive in 36 (38.3%) and negative in 58 (61.7%) cases. The results revealed that MIIP protein expression was downregulated in cancer tissues, a finding in concordance with the mRNA expression result. The association between MIIP expression in NSCLC tissues and various clinicopathological parameters was also analyzed. Analysis of MIIP expression revealed that expression was significantly associated with pathology and tumor staging (P=0.014 and P=0.002, respectively), but not with gender, age or NSCLC differentiation status (all P>0.05), as shown in Table III. To determine whether the downregulation of MIIP protein expression was correlated with disease progression, the staining degrees within tumor staging groups were compared. The results demonstrated that the positive percentage of MIIP protein expression was significantly reduced in advanced tumor stage samples, as compared with specimens from less advanced tumors (Fig. 2B; Table III).


Clinical significance of migration and invasion inhibitor protein expression in non-small-cell lung cancer.

Wang X, Liu H, Wang X, An Y - Oncol Lett (2014)

Examples of migration and invasion inhibitor protein immunostaining in non-small cell lung carcinoma samples. (A) Adenocarcinoma; and (B) squamous cell carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214401&req=5

f3-ol-08-06-2417: Examples of migration and invasion inhibitor protein immunostaining in non-small cell lung carcinoma samples. (A) Adenocarcinoma; and (B) squamous cell carcinoma.
Mentions: Immunohistochemical staining of MIIP in the cancer tissue sections was conducted. Immunoreactivity for the MIIP antibody was predominantly identified in the cytoplasm of cancer cells with marginal immunoreactivity in the nucleus (Fig. 3). Among the 94 tissue samples, MIIP protein expression was positive in 36 (38.3%) and negative in 58 (61.7%) cases. The results revealed that MIIP protein expression was downregulated in cancer tissues, a finding in concordance with the mRNA expression result. The association between MIIP expression in NSCLC tissues and various clinicopathological parameters was also analyzed. Analysis of MIIP expression revealed that expression was significantly associated with pathology and tumor staging (P=0.014 and P=0.002, respectively), but not with gender, age or NSCLC differentiation status (all P>0.05), as shown in Table III. To determine whether the downregulation of MIIP protein expression was correlated with disease progression, the staining degrees within tumor staging groups were compared. The results demonstrated that the positive percentage of MIIP protein expression was significantly reduced in advanced tumor stage samples, as compared with specimens from less advanced tumors (Fig. 2B; Table III).

Bottom Line: The results revealed that MIIP mRNA and protein expression were downregulated in cancer tissues, as compared with the matched normal tissues.MIIP expression levels were significantly associated with pathology and tumor stage, with reduced MIIP mRNA expression levels detected in advanced tumor stage samples.Furthermore, patients with MIIP-positive protein expression had an improved prognosis as compared with those patients with MIIP-negative protein expression, with five-year survival rates of 41.7 and 22.4%, respectively (Kaplan-Meier, log-rank, P=0.028).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China.

ABSTRACT
Migration and invasion inhibitor protein (MIIP) was initially identified in a yeast two-hybrid screen. Recently, MIIP has emerged as a key protein in regulating cell migration and invasion. However, the MIIP expression profile in non-small-cell lung cancer (NSCLC) has not been analyzed. In the present study, MIIP mRNA expression levels were evaluated using the SYBR Green quantitative real-time polymerase chain reaction method in 37 NSCLC specimens and matched normal tissue samples. MIIP protein expression in a further 94 NSCLC specimens was examined with immunohistochemistry. Patient survival data were collected retrospectively, and the association between MIIP protein expression and the five-year overall survival rate was evaluated. The results revealed that MIIP mRNA and protein expression were downregulated in cancer tissues, as compared with the matched normal tissues. MIIP expression levels were significantly associated with pathology and tumor stage, with reduced MIIP mRNA expression levels detected in advanced tumor stage samples. Furthermore, patients with MIIP-positive protein expression had an improved prognosis as compared with those patients with MIIP-negative protein expression, with five-year survival rates of 41.7 and 22.4%, respectively (Kaplan-Meier, log-rank, P=0.028). A significant association between MIIP protein expression and improved prognosis was also demonstrated using univariate and multivariate analyses (P=0.033 and P=0.040, respectively). These results suggest that MIIP may have a potential role in the pathogenesis of NSCLC and also confirm that MIIP is a putative tumor-suppressor gene. Therefore, MIIP may be identified as a functional genetic marker of NSCLC development and prognosis, and may be an attractive therapeutic target for the treatment of lung cancer.

No MeSH data available.


Related in: MedlinePlus